Table 2.

Phase I/II clinical trials of CTLA-4 blockade

Antibodies	Dose	Cancer	No. of cases	No. of objective responses	Reference
MDX-010	3 mg/kg, 1.5 mg/kg every 4 weeks	Lymphoma	4	2	(63)
		Colon	3	0
		Prostate	4	0
MDX-010	3 mg/kg	Prostate	14	2 (≥50% decrease of prostate-specific antigen)	(58)
MDX-010	3 mg/kg every 3 weeks	Renal	21	1 partial response	(66)
MDX-010	3 mg/kg, 1 mg/kg every 3 weeks	Renal	38	5 partial responses	(66)
MDX-010	3 mg/kg	Melanoma	7	0	(57)
MDX-010	3 mg/kg	Ovarian	2	0	(57)
MDX-010	3 mg/kg every 4 weeks	Melanoma	37	2 partial responses	(69)
MDX-010 + dacarbazine		Melanoma	35	1 complete response
MDX-010 + dacarbazine				5 partial responses
MDX-010	1-3 mg/kg	Renal	61	7	(64)
MDX-010 ± gp100 peptide	1-9 mg/kg	Melanoma	137	20
MDX-010 + gp100 peptide	3 mg/kg every 3 weeks	Melanoma	14	2 complete responses	(61)
MDX-010 + gp100 peptide				1 partial response	(61)

MDX-010 + gp100 peptide	3 mg/kg every 3 weeks	Melanoma	29	2 complete responses	(60)
				2 partial responses

	1-3 mg/kg, 1 mg/kg every 3 weeks	Melanoma	27	3 partial responses
MDX-010 + IL-2	1 mg/kg × 3-6	Melanoma	6	1 partial response	(65)
	2 mg/kg × 3-7	Melanoma	3	1 complete response
	3 mg/kg × 1-9	Melanoma	27	2 complete responses
				4 partial responses
MDX-010 + peptide	0.3-3 mg/kg every 3 weeks	Melanoma	19	7	(62)
MDX-010 + GVAX	3 mg/kg	Prostate	6	5 (≥50% decrease of prostate-specific antigen)	(70)
CP-675,206	0.01-15 mg/kg × 1	Melanoma	34	2 complete responses	(59)
				2 partial responses
		Renal	4	0
		Colon	1	0
CP-675, 206	3-10 mg/kg every 4 weeks	Melanoma	14	1	(67)
CP-675, 206	10 mg/kg every 4 weeks	Melanoma	16	3	(68)
CP-675, 206	15 mg/kg every 12 weeks	Melanoma	10	2	(68)